Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Inflammatory Bowel Diseases

  Free Subscription


1 Aliment Pharmacol Ther
1 BMC Gastroenterol
3 Dig Dis Sci
3 Eur J Gastroenterol Hepatol
2 Gastroenterology
9 Inflamm Bowel Dis
7 J Crohns Colitis
2 PLoS One
1 Scand J Gastroenterol
1 Z Gastroenterol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Aliment Pharmacol Ther

  1. BOKEMEYER B, Plachta-Danielzik S
    Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It depends on how you use the drug. Authors' reply.
    Aliment Pharmacol Ther. 2023 Nov 4. doi: 10.1111/apt.17796.

    BMC Gastroenterol

  2. BOERKOEL A, Tischler L, Kaul K, Krause H, et al
    Healthcare service use in paediatric inflammatory bowel disease: a questionnaire on patient and parent care experiences in Germany.
    BMC Gastroenterol. 2023;23:378.
    PubMed         Abstract available

    Dig Dis Sci

  3. VALDES-DELGADO T, Aguado-Paredes A, Merino-Bohorquez V, Martin-Manzanares J, et al
    Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.
    Dig Dis Sci. 2023 Nov 9. doi: 10.1007/s10620-023-08139.
    PubMed         Abstract available

  4. MASSIRONI S, Laffusa A, Parigi TL, Danese S, et al
    Standardizing Endoscopic Reporting in Patients with IBD: JEDII to the Rescue?
    Dig Dis Sci. 2023;68:4287-4289.

  5. CONSTANT BD, Scott FI
    The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance?
    Dig Dis Sci. 2023;68:4279-4281.

    Eur J Gastroenterol Hepatol

  6. SONNENBERG A, Duong HT, McCarty DJ, El-Serag HB, et al
    Concurrence of inflammatory bowel disease with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2023;35:1349-1353.
    PubMed         Abstract available

  7. STJARNGRIM J, Ekbom A, Widman L, Hultcrantz R, et al
    Post-colonoscopy rectal cancer in Swedish patients with Crohn's disease 2001-2015: a population-based case review study.
    Eur J Gastroenterol Hepatol. 2023;35:1334-1340.
    PubMed         Abstract available

  8. NGUYEN AL, Herath M, Burns M, Holt D, et al
    The value of whole-body dual-energy x-ray absorptiometry in assessing body composition in patients with inflammatory bowel disease: a prospective study.
    Eur J Gastroenterol Hepatol. 2023 Nov 7. doi: 10.1097/MEG.0000000000002675.
    PubMed         Abstract available


  9. WINE E
    Could gut and food-derived yeast be responsible for activating T-cells in Crohn disease?
    Gastroenterology. 2023 Nov 3:S0016-5085(23)05204.

    Mirikizumab for the Management of Ulcerative Colitis.
    Gastroenterology. 2023 Nov 3:S0016-5085(23)05206.

    Inflamm Bowel Dis

  11. LUO Y, Schmidt N, Dubinsky MC, Jaffin B, et al
    Evaluating lleal Pouch Anal Anastomosis Function: Time to Expand Our ARM-amentarium.
    Inflamm Bowel Dis. 2023;29:1819-1825.
    PubMed         Abstract available

  12. CHANG S, Hong S, Hudesman D, Remzi F, et al
    Histologic Predictors of Clinical Outcomes and Healthcare Utilization in Patients With Ileal Pouch-Anal Anastomosis.
    Inflamm Bowel Dis. 2023;29:1769-1777.
    PubMed         Abstract available

  13. RIGGOTT C, Fairbrass KM, Selinger CP, Gracie DJ, et al
    Impact of Opioid Use on the Natural History of Inflammatory Bowel Disease: Prospective Longitudinal Follow-up Study.
    Inflamm Bowel Dis. 2023 Oct 31:izad256. doi: 10.1093.
    PubMed         Abstract available

  14. NARDONE OM, Calabrese G, Barberio B, Giglio MC, et al
    Rates of Endoscopic Recurrence In Postoperative Crohn's Disease Based on Anastomotic Techniques: A Systematic Review And Meta-Analysis.
    Inflamm Bowel Dis. 2023 Nov 1:izad252. doi: 10.1093.
    PubMed         Abstract available

  15. FEATHERS A, Lovasi GS, Grigoryan Z, Beem K, et al
    Crohn's Disease Mortality and Ambient Air Pollution in New York City.
    Inflamm Bowel Dis. 2023 Nov 2:izad243. doi: 10.1093.
    PubMed         Abstract available

  16. RUBIN DT, Torres J, Dotan I, Xu LT, et al
    An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts.
    Inflamm Bowel Dis. 2023 Nov 2:izad247. doi: 10.1093.
    PubMed         Abstract available

  17. TUBAU-JUNI N, Hontecillas R, Leber AJ, Alva SS, et al
    Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.
    Inflamm Bowel Dis. 2023 Nov 2:izad258. doi: 10.1093.
    PubMed         Abstract available

  18. GONZALEZ CUETO E, Edmans M, Wellens J, Cadwell K, et al
    Antibody, not Cellular, Immune Responses to SARS-CoV-2 Vaccination Outperform Infection in Inflammatory Bowel Disease Patients.
    Inflamm Bowel Dis. 2023 Nov 3:izad265. doi: 10.1093.

  19. CHEW DCH, Khoo XH, Lee TS, Chin KY, et al
    A Systematic Review on the Increasing Incidence of Inflammatory Bowel Disease in Southeast Asia: Looking Beyond the Urbanization Phenomenon.
    Inflamm Bowel Dis. 2023 Nov 3:izad189. doi: 10.1093.
    PubMed         Abstract available

    J Crohns Colitis

  20. GISBERT JP, Chaparro M
    De-escalation of biological treatment in inflammatory bowel disease: A comprehensive review.
    J Crohns Colitis. 2023 Nov 1:jjad181. doi: 10.1093.
    PubMed         Abstract available

  21. RAINE T, Ishiguro Y, Rubin DT, Finney-Hayward T, et al
    Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: a Post Hoc Analysis of the Phase 3 Clinical Trial Programme.
    J Crohns Colitis. 2023 Nov 6:jjad190. doi: 10.1093.
    PubMed         Abstract available

  22. LIU Z, Alexander JL, Eng KY, Ibraheim H, et al
    Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
    J Crohns Colitis. 2023 Nov 6:jjad182. doi: 10.1093.
    PubMed         Abstract available

  23. VERMEIRE S, Hanzel J, Lowenberg M, Ferrante M, et al
    Early versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.
    J Crohns Colitis. 2023 Nov 2:jjad179. doi: 10.1093.
    PubMed         Abstract available

  24. ROBLIN X, Nancey S, Papamichael K, Duru G, et al
    Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease.
    J Crohns Colitis. 2023 Nov 2:jjad188. doi: 10.1093.
    PubMed         Abstract available

  25. VUYYURU SK, Solitano V, Narula N, Lee MJ, et al
    Pharmacological therapies for the management of fistulising Crohn's disease: A systematic review and meta-analysis.
    J Crohns Colitis. 2023 Nov 2:jjad185. doi: 10.1093.
    PubMed         Abstract available

  26. CASAS DEZA D, Polo Cuadro C, de Francisco R, Vela Gonzalez M, et al
    Initial management of intraabdominal abscesses and preventive strategies for abscess recurrence in penetrating Crohn's disease: a national multicenter study based on ENEIDA registry.
    J Crohns Colitis. 2023 Nov 1:jjad184. doi: 10.1093.
    PubMed         Abstract available

    PLoS One

  27. OTT A, Tutdibi E, Goedicke-Fritz S, Schope J, et al
    Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease.
    PLoS One. 2023;18:e0288147.
    PubMed         Abstract available

  28. KONECNY AJ, Shows DM, Lord JD
    Colonic mucosal associated invariant T cells in Crohn's disease have a diverse and non-public T cell receptor beta chain repertoire.
    PLoS One. 2023;18:e0285918.
    PubMed         Abstract available

    Scand J Gastroenterol

  29. IBORRA M, Ferreiro-Iglesias R, Maria Dolores MA, Mesonero Gismero F, et al
    Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
    Scand J Gastroenterol. 2023 Nov 6:1-9. doi: 10.1080/00365521.2023.2278427.
    PubMed         Abstract available

    Z Gastroenterol

  30. REIDER S, Novacek G, Haas T, Grochenig HP, et al
    [Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (OGGH)].
    Z Gastroenterol. 2023;61:1518-1525.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.